Sarasota Film Festival award winners announced
“Best Summer Ever,” a movie that puts a new spin on the teen musical genre, won the best narrative jury prize at the 2021 Sarasota Film Festival, which was presented at the CMX CinéBistro Siesta Key and online April 30-May 9.
The film by Michael Parks Randa and Lauren Smittelli featured eight original songs and a cast and crew made up of people with and without disabilities.
Eden Wurmfeld and Margaret Munzer Loe’s “Chasing Childhood” won the documentary feature jury prize. The jury award for best U.S. narrative short went to “Harana” by Marie Jamora. Said Hamich’s “The Departure” was named best international short, and David Baram’s “One All the Way” won the prize for best documentary short.
Bunny Wailer (centre) poses for a photo with Chris Chin (second right), head of VP Records; Wailer’s manager, Maxine Stowe (second left); Abijah Asadenaki (left), Jah B’s eldest son, and reggae artiste, Blak Hero (right). The occasion was the signing of a licensing deal with VP Records for Bunny Wailer’s music.
Carl Livingston, co-executor of Bunny Wailer’s estate, has stepped in, purportedly as a voice of reason, and made an appeal for calm among younger members of the Livingston clan, calling for them to wake up and smell the coffee .
In an interview, Bunny Wailer’s older brother told Loop News that: Abijah and his siblings need to settle down and decide to come together and do the necessary things to get his dad situated, then after that you can do all the bickering, talk and the side shows.
Bunny Wailer
Abijah Asadenaki Livingston, co-executor of Bunny Wailer’s estate, has issued a statement on Facebook where he has denied that the family has any objection to any deal with VP Records regarding the completion of a licensing deal that will allow the family to settle an outstanding hospital bill.
The outstanding hospital bill has to be settled so that the family can obtain a death certificate, and hence go ahead and plan the burial.
“My siblings and I are not against any deal with VP records. However, with the responsibility that my father has entrusted me as an executor, I cannot blindly sign any agreement concerning his intellectual property without reviewing the details of the contract especially knowing how protective my father was of his works,” the statement said.
Published: Jan 13, 2021 By Brandon May
Jonathan Weiss/Shutterstock
Major players in the biotech industry are moving full steam ahead in their 2021 operations goals despite the ongoing pandemic, with global pharmaceutical giant Takeda being no exception. The Japanese biopharmaceutical company
just announced it has entered into a broad strategic collaboration with KSQ Therapeutics to research, develop and commercialize novel immune-oncology agents using the latter company’s proprietary CRISPRomics® discovery platform.
The discovery platform will be used in clinical research to screen the entire human genome in an effort to find optimal gene targets for autoimmune and oncology disease. Under terms of the agreement, Takeda will obtain exclusive, worldwide and royalty-bearing license to develop, manufacturer and commercialize both cell and non-cell therapy candidates for the modulation of targets identified with KSQ’s CRISPRomics platform.
AnGes Acquires Gene Editing Company EmendoBio
Share
Rare Daily Staff
The Japanese biopharmaceutical company AnGes has acquired the next-generation gene editing company EmendoBio at a valuation of $250 million.
EmendoBio will operate as an independent wholly owned subsidiary of AnGes and will continue to maintain its business operations at its facilities in New York and Tel Aviv, Israel. The acquisition was completed on December 15, 2020.
EmendoBio is pioneering its OMNI technologies, a next-generation novel nuclease discovery platform and a nuclease optimization platform that incorporate protein engineering and directed evolution capabilities. The company said its technology enables previously undemonstrated high levels of precision gene editing and target specific optimization to make any gene targetable, unlocking a way to treat a broad range of genetic diseases including many previously considered untreatable.